Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

July 24th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Dr. Kurtz on the Clinical Utility of Cell-Free DNA in Lymphoma

July 24th 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses the utility of cell-free DNA in lymphoma.

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin Lymphoma

July 24th 2018

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses the aim of the ECHELON-1 study in classical Hodgkin lymphoma.

Lenalidomide/Rituximab Improves PFS in Phase III Indolent Lymphoma Study

July 24th 2018

Combining lenalidomide with rituximab significantly improved progression-free survival compared with rituximab alone for the treatment of patients with relapsed/refractory indolent lymphoma.

Goy Discusses Latest Lymphoma Data

July 24th 2018

Andre Goy, MD, discusses some of the most important lymphoma data presented at the 2018 ASCO Annual Meeting and potential future directions for treatment.

Dr. Lunning Discusses the Treatment of Peripheral T-Cell Lymphoma

July 23rd 2018

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.

Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

July 23rd 2018

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Dr. Hobbs on the Updated NCCN Guidelines in CML

July 20th 2018

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).

Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

July 20th 2018

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Smith Discusses Brentuximab Vedotin in CTCL

July 20th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

Ansell Discusses Combination Potential in Hodgkin Lymphoma

July 20th 2018

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

FDA Approves Ivosidenib for IDH1+ AML

July 20th 2018

The FDA has approved ivosidenib for the treatment of adult patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

July 20th 2018

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Immunotherapy at the Forefront of ALL Treatment, Expert Says

July 20th 2018

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma

July 20th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Dr. Kahl Discusses Polatuzumab Vedotin in Lymphoma

July 20th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma

July 20th 2018

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Treatment Options for CD30-Positive PTCL Subtypes

July 19th 2018

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.